 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Aug 20, 2018 |
| Title |
Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Coordinately Regulates Multiple Survival Pathways to Reduce Cellular Proliferation and Survival in Cutaneous T-Cell Lymphoma |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
miR-155 is a microRNA associated with poor prognosis in lymphoma and leukemia and has been implicated in the progression of Mycosis Fungoides (MF), the most common form of cutaneous T-cell lymphoma (CTCL). In this study, we developed and tested Cobomarsen (MRG-106), a locked nucleic acid-modified oligonucleotide inhibitor of miR-155. In MF cell lines in vitro, inhibition of miR-155 with Cobomarsen de-repressed direct miR-155 targets, decreased expression of multiple gene pathways associated with cell survival, reduced survival signaling, decreased cell proliferation, and activated apoptosis.
We identified a set of genes that are significantly regulated by Cobomarsen, which includes direct and downstream targets of miR-155.
|
| |
|
| Overall design |
CTCL cell lines were cultured with Cobomarsen (MRG-106) for 4 days (to identify direct targets) or 8 days (to identify downstream targets).
|
| |
|
| Contributor(s) |
Seto AG, Jackson AL, Lynch JM |
| Citation(s) |
30125933 |
| |
| Submission date |
Mar 23, 2018 |
| Last update date |
Mar 25, 2019 |
| Contact name |
Aimee Jackson |
| Organization name |
miRagen Therapeutics
|
| Street address |
6200 Lookout Rd.
|
| City |
Boulder |
| State/province |
CO |
| ZIP/Postal code |
80301 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL570 |
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array |
|
| Samples (56)
|
|
| Relations |
| BioProject |
PRJNA445443 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE112273_RAW.tar |
296.3 Mb |
(http)(custom) |
TAR (of CEL, CHP) |
| Processed data included within Sample table |
| Processed data provided as supplementary file |
|
|
|
|
 |
Less...
More...